Abstract Background Immune checkpoint inhibitors (ICIs) with angiogenesis inhibitors have
been used to treat advanced lung cancer. Their associated treatment-related adverse events …

Background. Apatinib is established to be the standard of care as third‐line therapy for
patients with previously treated advanced gastric cancer (GC). Programmed cell death …

A 67‐year‐old male patient presented with extensive‐stage small cell lung cancer with the
primary lesion located in the right upper lung, accompanied by multiple metastases to the …

Purpose This study was to investigate the efficacy and safety of anlotinib combined with
programmed cell death protein 1 (PD-1) blockades for patients with previously treated …

Objective To investigate the clinical efficacy and safety of anlotinib combined with anti-PD-1
inhibitors in the 2nd or later-line treatment of advanced solid tumors. Patients and Methods A …

Objective This study was to investigate the effectiveness and tolerability of anlotinib plus PD-
1 inhibitors for patients with previously treated metastatic soft tissue sarcoma (STS). Methods …

Objective Therapeutic regimens are relatively scarce among patients with treatment-
refractory metastatic colorectal cancer (CRC). This study aimed to determine the feasibility …

Background Anlotinib, as a salvage treatment for patients after failure of third-line or later-
line treatments for small cell lung cancer (SCLC), has shown efficacy in patients with brain …

Background Patients with relapsed small cell lung cancer (SCLC) have limited treatment
options and dismal survival. Phase II study shows the moderate activity of anlotinib …

Objective Lenvatinib was the standard first-line therapy for patients with unresectable HCC.
PD-1 blockades demonstrated promising efficacy for patients with previously-treated HCC …